Outcomes of adults and children with primary mediastinal B‐cell lymphoma treated with dose‐adjusted EPOCH‐R

• DOI: 10.1111/bjh.14951
• Publication Date: 2017-10-30T04:46:38Z
• Authors: Lisa Giulino‐Roth; Tara O'Donohue; Zhengming Chen; Nancy L. Bartlett; Ann LaCasce; William Martin‐Doyle; Matthew J. Barth; Kimberly Davies; Kristie A. Blum; Beth Christian; Carla Casulo; Sonali M. Smith; James Godfrey; Amanda Termuhlen; Matthew J. Oberley; Sarah Alexander; Sheila Weitzman; Burton Appel; Benjamin Mizukawa; Jakub Svoboda; Zeinab Afify; Melinda Pauly; Hema Dave; Rebecca Gardner; Deborah M. Stephens; William A. Zeitler; Christopher Forlenza; Jennifer Levine; Michael E. Williams; Jody L. Sima; Catherine M. Bollard; John P. Leonard
• Keywords: Epoch (astronomy)

Summary Treatment with dose‐adjusted EPOCH (etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone) chemotherapy and rituximab ( DA ‐ ‐R) has become the standard of care for primary mediastinal B‐cell lymphoma PMBCL ) at many institutions despite limited data in multi‐centre setting. We report a large, retrospective analysis children adults treated ‐R to characterize outcomes evaluate prognostic factors. assessed 156 patients across 24 academic centres, including 38 118 adults. All received least one cycle ‐R. Radiation therapy was administered 14·9% patients. With median follow‐up 22·6 months, estimated 3‐year event‐free survival EFS 85·9% [95% confidence interval CI 80·3–91·5] overall 95·4% (95% 91·8–99·0). Outcomes were not statistically different between paediatric adult Thrombotic complications reported 28·2% more common (45·9% vs. 22·9%, P = 0·011). Seventy‐five per cent had negative fluorodeoxyglucose positron emission tomography FDG PET scan completion ‐R, defined as Deauville score 1–3. Negative end‐of‐therapy associated improved (95·4% 54·9%, < 0·001). Our support use treatment Patients positive have an inferior outcome.